Study of rSIFN-co for Patients With Advanced Solid Tumors

Stopped Protocol has been amended and the Protocol amendment of Phase II was approved by the US FDA on Nov 2024 through SN0028.

Conditions

• Malignancies Including Melanoma, Kidney, Lung, Colorectal, Prostate, Neuroendocrine Tumor

Interventions

• BIOLOGICAL: rSIFN-co

Sponsor

Sichuan Huiyang Life Science and Technology Corporation

Collaborators

• [object Object]